← Research index  ·  Disorder page  ·  Source YAML

Cross-provider research synthesis

APL PML RARA

MONDO:0012883 Curated 2026-07-04T00:00:00Z 9 harmonized findings
falcon · 26 citations openscientist · 52 citations
Concordant asserts the finding Partial supports a weaker/qualified form Contradictory conflicts with it Silent does not address it

Harmonized findings

APL is driven by the balanced t(15;17) translocation, which fuses PML to RARA to create the PML-RARA fusion oncoprotein that enforces a myeloid differentiation block at the promyelocyte stage.

UNANIMOUS INTEGRATED
pathophysiologygenetic_factor
ProviderStanceScoreEvidence
falcon CONCORDANT 95% Balanced translocation t(15;17) generating PML::RARA fusion; fusion acts as a transcriptional repressor, blocks myeloid differentiation, and disrupts PML nuclear bodies
Falcon names the t(15;17) PML::RARA fusion as the primary causal lesion that blocks myeloid differentiation.
DOI:10.3389/fonc.2022.1062524
openscientist CONCORDANT 97% Acute Promyelocytic Leukemia (APL) is a distinct subtype of acute myeloid leukemia characterized by a block in myeloid differentiation at the promyelocyte stage, caused by the PML-RARA fusion oncoprotein resulting from the t(15;17)(q24;q21) chromosomal translocation.
OpenScientist gives the same driver mechanism with the full cytogenetic coordinates t(15;17)(q24;q21).
PMID:34193815

PML-RARA acts through a dual mechanism, functioning as a transcriptional repressor of RARA target genes while simultaneously disrupting the formation and tumor-suppressor function of PML nuclear bodies.

UNANIMOUS INTEGRATED
pathophysiologygene_function
ProviderStanceScoreEvidence
falcon CONCORDANT 90% represses the transcription of RARa target genes and disrupts PML nuclear bodies, with subsequent impairment of differentiation, self-renewal, and response to DNA damage.
Falcon quotes a review describing repression of RARa targets plus PML nuclear body disruption impairing differentiation, self-renewal, and DNA-damage response.
DOI:10.3390/cancers16244192
openscientist CONCORDANT 95% Mechanistically, PML-RARa acts as a transcriptional repressor of RARa and non-RARa target genes and antagonizes the formation and function of PML nuclear bodies that regulate numerous signaling pathways
OpenScientist quotes the same dual repressor / PML-nuclear-body-antagonist mechanism.
PMID:24344243

Combination differentiation therapy with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) has transformed APL into the most curable AML subtype, with long-term/5-year overall survival rising to over 90%.

UNANIMOUS INTEGRATED
treatmentprognosis
ProviderStanceScoreEvidence
falcon CONCORDANT 90% with ATRA+ATO-based molecularly targeted therapy (often quoted as >90% long-term survival in contemporary series), making it a flagship of targeted differentiation therapy.
Falcon frames APL as highly curable with ATRA+ATO and >90% long-term survival, a flagship of targeted differentiation therapy.
DOI:10.3389/fonc.2022.1062524
openscientist CONCORDANT 95% The introduction of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) has transformed APL from the most lethal to the most curable subtype of AML, with 5-year overall survival rates improving from less than 35% to over 90-95%.
OpenScientist quantifies the transformation, giving the pre-therapy (<35%) to modern (>90-95%) 5-year OS improvement.
PMID:40623894

ATRA and ATO work by dual targeting of the two moieties of the fusion: ATRA relieves RARA-driven repression and degrades PML-RARA to restore differentiation, while ATO binds the PML B-box 2 domain, triggering SUMOylation/ubiquitination-dependent degradation and restoration of PML nuclear bodies.

UNANIMOUS INTEGRATED
pathophysiologytreatment
ProviderStanceScoreEvidence
falcon CONCORDANT 85% Primary mechanistic literature and reviews converge on a pathway where ATO binding to the PML moiety drives post-translational modifications (SUMOylation/ubiquitination) leading to fusion degradation
Falcon describes the ATO -> PML-moiety-binding -> SUMOylation/ubiquitination -> fusion degradation cascade (citing PIAS1/RNF4 roles), matching the ATO arm.
DOI:10.1038/s41418-023-01139-8, DOI:10.3390/cancers16071351
openscientist CONCORDANT 95% ATRA overcomes the differentiation block by degrading PML-RARA and restoring normal myeloid maturation, while ATO directly binds to the PML moiety, triggering SUMOylation-dependent degradation of the fusion protein and restoration of PML nuclear bodies.
OpenScientist gives both arms explicitly and adds the PML B-box 2 arsenic-binding structural detail.
PMID:37655965, PMID:32223133

A severe hemorrhagic coagulopathy (disseminated intravascular coagulation with hyperfibrinolysis) is the hallmark presenting complication of APL and the leading cause of early death.

UNANIMOUS INTEGRATED
phenotype
ProviderStanceScoreEvidence
falcon CONCORDANT 90% Characteristic aggressive coagulopathy with DIC and primary hyperfibrinolysis; severe hemorrhagic syndrome is a major cause of early death, often involving cerebral or pulmonary bleeding
Falcon names DIC/hyperfibrinolysis and severe hemorrhage as the hallmark and a major cause of early death.
DOI:10.3390/futurepharmacol3010012
openscientist CONCORDANT 90% presents with a characteristic life-threatening coagulopathy -- disseminated intravascular coagulation (DIC) -- that causes hemorrhagic early death in up to 30% of patients in real-world settings.
OpenScientist matches the DIC hallmark and links it to hemorrhagic early death in up to 30% of real-world patients.
PMID:33860520

Early death within 30 days of diagnosis (predominantly from hemorrhage) remains the principal barrier to universal cure, reaching up to 30% in real-world population-based settings despite trial cure rates over 90%.

UNANIMOUS INTEGRATED
prognosis
ProviderStanceScoreEvidence
falcon CONCORDANT 85% Early death remains the major obstacle to cure; real-world studies reported 30-day/very-early death burdens, including 144 early deaths in a 1991–2021 population cohort and 12.5% 7-day early death in a single-center cohort
Falcon identifies early death as the major obstacle to cure with concrete real-world 30-day and 7-day death burdens.
DOI:10.1186/s12885-023-10612-z
openscientist CONCORDANT 95% early death (ED)-occurring within 30 days of diagnosis-remains unacceptably high, reaching up to 30% in population-based studies. ED is the major barrier to universal cure, with fatal hemorrhage as the predominant cause, followed by infection, differentiation syndrome, and thrombosis
OpenScientist quantifies ED at up to 30% and ranks the causes, naming fatal hemorrhage as predominant.
PMID:41440532

PML-RARA silences differentiation genes epigenetically by recruiting chromatin repressor complexes (NuRD, DNA methyltransferases, and Polycomb/PRC2) to target promoters such as RARbeta2.

SINGLE LEAD
pathophysiologygene_function
ProviderStanceScoreEvidence
openscientist CONCORDANT 90% PML-RARa binds and recruits NuRD to target genes, including to the tumor-suppressor gene RARbeta2. In turn, the NuRD complex facilitates Polycomb binding and histone methylation at lysine 27
OpenScientist details the NuRD -> Polycomb / H3K27me3 epigenetic repressor hierarchy recruited by PML-RARA, plus DNMT recruitment.
PMID:18644863
falcon SILENT —
Falcon covers PML-RARA transcriptional repression and PML-nuclear-body post-translational modification (SUMOylation/ubiquitination, HDAC3), but does not describe recruitment of NuRD/DNMT/Polycomb chromatin-repressor complexes to silence differentiation genes.

Cooperating somatic co-mutations (notably FLT3-ITD in roughly 20-40% of cases, plus WT1, NRAS and KRAS) occur alongside the fusion and may modify prognosis.

MAJORITY LEAD
genetic_factor
ProviderStanceScoreEvidence
openscientist CONCORDANT 90% Present in approximately 20-40% of APL cases; associated with higher WBC counts and the microgranular variant.
OpenScientist quantifies FLT3-ITD at ~20-40% and lists additional cooperating mutations (FLT3-D835, WT1, NRAS/KRAS).
PMID:36539954
falcon PARTIAL 50% occur and may affect prognosis, supporting broader molecular profiling beyond the fusion transcript in some contexts.
Falcon lists co-mutations (FLT3, WT1, NRAS, KRAS) that may affect prognosis but gives no frequencies, so it is partial relative to the quantified finding.
DOI:10.3390/cancers16183208

Therapy-related APL arises after exposure to topoisomerase II inhibitors (e.g., mitoxantrone, etoposide, doxorubicin), which generate the t(15;17) translocation via topoisomerase II-mediated DNA cleavage at PML and RARA.

SINGLE LEAD
genetic_factorepidemiology
ProviderStanceScoreEvidence
openscientist CONCORDANT 90% Therapy-related APL (t-APL) arises after exposure to topoisomerase II inhibitors (e.g., mitoxantrone, etoposide, doxorubicin)
OpenScientist describes t-APL and the topoisomerase IIalpha-mediated DNA cleavage mechanism generating the translocation.
PMID:18650449, PMID:15899774
falcon SILENT —
Falcon explicitly reports that no specific environmental or infectious etiologic agents were extractable from its retrieved evidence, so it does not cover the topoisomerase II inhibitor / therapy-related APL etiology. This is a coverage gap in Falcon's retrieval, not a contradiction.

Narrative

Overview

Both providers frame acute promyelocytic leukemia as a genetically defined AML subtype driven by the t(15;17) PML-RARA fusion oncoprotein, which blocks promyelocyte differentiation and disrupts PML nuclear bodies. Both center the same clinical story: a life-threatening DIC/hemorrhagic coagulopathy, a historic transformation to the most curable AML by ATRA plus arsenic trioxide differentiation therapy, and early death as the remaining barrier to cure.

Agreement

The reports converge tightly on the core biology and therapy: the fusion driver and differentiation block; the dual repressor / PML-nuclear-body mechanism; the dual-moiety mechanism of ATRA (RARA arm) and ATO (PML B-box 2 -> SUMOylation/ ubiquitination degradation); the DIC coagulopathy hallmark; the transformation to >90% survival with ATRA+ATO; and early death within 30 days (up to ~30% in real-world cohorts, hemorrhage predominant) as the principal unmet challenge.

Divergence

Divergence is coverage/depth rather than conflict. OpenScientist (52 citations) adds substantial molecular and clinical granularity that Falcon (26 citations) omits: the epigenetic repressor hierarchy (NuRD -> Polycomb/H3K27me3, DNMT recruitment), quantified cooperating mutations (FLT3-ITD ~20-40%, WT1, NRAS/ KRAS), therapy-related APL via topoisomerase II inhibitors, PML B-box2 ATO resistance mutations, breakpoint cluster regions, Sanz risk stratification, immunophenotype, and detailed treatment regimens. Falcon explicitly notes that environmental etiologies and several identifiers were not extractable from its retrieved evidence, which is why it is silent (not contradictory) on t-APL and the epigenetic-complex mechanism. No direct contradictions were found between the two reports.

Integration

The concordant core findings (fusion driver and differentiation block, dual repressor / PML-nuclear-body mechanism, ATRA/ATO dual-moiety mechanism, DIC coagulopathy hallmark, ATRA+ATO curability, and early-death barrier) are suitable for integration into kb/disorders/APL_PML_RARA.yaml pathophysiology, treatment, phenotype, and prognosis blocks, anchored on the verified PMIDs/DOIs each provider cites.

Not integrated (leads)

The OpenScientist-only depth (epigenetic NuRD/Polycomb recruitment, quantified cooperating mutations, and topoisomerase II-mediated therapy-related APL) is retained as research leads pending independent PMID/snippet verification before promotion, rather than integrated directly from the synthesis.

Cross-provider synthesis comparing falcon (pathophysiology/outcomes-focused, 26 citations) and openscientist (comprehensive 15-domain, 52 citations). Agreement is strong on driver biology, ATRA/ATO mechanism and curability, coagulopathy, and early-death burden; divergence is coverage/depth (OpenScientist adds epigenetic, cooperating-mutation, and therapy-related-APL detail Falcon does not retrieve), with no direct contradictions. best_matching_text values are verbatim excerpts from the cited report files; literature evidence snippets are intentionally left for the main curation pipeline after fetch-reference verification.